Publications
Joshi JN, Lerner AD, Scallo F, Grumet AN, Matteson P, Millonig JH, Valvezan AJ.
mTORC1 activity oscillates throughout the cell cycle promoting mitotic entry and differentially influencing autophagy
bioRxiv. Feb 2024
Liu X, Jones WD, Quesnel-Vallières M, Devadiga SA, Lorent K, Valvezan AJ, Myers RL, Li N, Lengner CJ, Barash Y, Pack M, Klein PS.
The Tumor Suppressor Adenomatous Polyposis Coli (apc) Is Required for Neural Crest-Dependent Craniofacial Development in Zebrafish
J Dev Biol., 11(3):29, Jun 2023.
Dai W, Shen J, Yan J, Bott AJ, Maimouni S, Daguplo HQ, Wang Y, Khayati K, Guo JY, Zhang L, Wang Y, Valvezan A, Ding WX, Chen X, Su X, Gao S, Zong WX.
Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1.
J Clin Invest,132(24):e161408, Dec 2022.
McNamara MC, Hosios AM, Torrence ME, Zhao T, Fraser C, Wilkinson M, Kwiatkowski DJ, Henske EP, Wu CL, Sarosiek KA, Valvezan AJ, Manning BD.
Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex.
iScience, 25(11):105458, Oct 2022.
Torrence ME, MacArthur MR, Hosios AM, Valvezan AJ, Asara JM, Mitchell JR, Manning BD.
The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals.
eLIFE, 1;10e63326, Mar 2021.
Valvezan AJ, McNamara MC, Miller SK, Torrence ME, Asara JM, Henske EP, Manning BD.
IMPDH inhibitors for anti-tumor therapy in tuberous sclerosis complex.
JCI Insight, 5(7):e135071, Apr 2020.
Valvezan AJ and Manning BD.
Molecular logic of mTORC1 signaling as a metabolic rheostat.
Nature Metabolism, 1:321-333, Mar 2019.
Valvezan AJ, Turner M, Belaid A, Lam HC, Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N, Kwiatkowski DJ, Asara JM, Henske EP, Manning BD.
mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability.
Cancer Cell, 32(5):624-638, Nov 2017.
Housden BE, Li Z, Kelley C, Wang Y, Hu Y, Valvezan AJ, Manning BD, Perrimon N.
Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA).
Proc Natl Acad Sci, 114(50):E10755-E10762, Nov 2017.
Filippakis H, Alesi N, Ogorek B, Nijmeh J, Khabibullin D, Gutierrez C, Valvezan AJ, Cunningham J, Priolo C, Henske EP.
Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R.
Oncotarget, 8(24):38099-38112, Jun 2017.
Li N, Yousefi M, Nakauka-Ddamba A, Li F, Vandivier L, Parada K, Woo DH, Wang S, Naqvi AS, Rao S, Tobias J, Cedeno RJ, Minuesa G, Y K, Barlowe TS, Valvezan A, Shankar S, Deering RP, Klein PS, Jensen ST, Kharas MG, Gregory BD, Yu Z, Lengner CJ.
The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins.
Cell Rep, 13(11):2440-55, Dec 2015.
Housden BE, Valvezan AJ, Kelley C, Sopko R, Hu Y, Roesel C, Lin S, Buckner M, Tao R, Yilmazel B, Mohr SE, Manning BD, Perrimon N.
Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi.
Sci Signal, 8(393), Sept 2015.
Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD.
Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.
Cell, 156(4):771-85, Feb 2014.
Valvezan AJ, Huang J, Lengner CJ, Pack M, Klein PS.
Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of rapamycin complex 1 (mTORC1) in mice and zebrafish.
Dis Model Mech, 7(1):63-71, Jan 2014.
Valvezan AJ, Zhang FS, Diehl JA, Klein PS.
Adenomatous Polyposis Coli (APC) regulates multiple signaling pathways by enhancing glycogen synthase kinase-3 (GSK-3) activity.
J Biol Chem, 287(6):3823-32, Feb 2012.
Valvezan AJ and Klein PS.
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder.
Front Mol Neurosci, 5:1, Jan 2012.